Abstract：Objective To analyze the effect of Rosuvastatin combined with Ticagrelor in the treatment of patients with coronary heart disease undergoing percutaneous coronary intervention.Methods Eighty patients with coronary heart disease who underwent percutaneous coronary intervention from April 2017 to April 2018 in our hospital were selected as research objects.The patients were divided into observation group （40 cases）and control group （40 cases）according to the computer random method.In the observation group，Rosuvastatin combined with Ticagrelor was adopted，and in the control group，conventional treatment was used.The total incidence rate of adverse cardiovascular events，total effective rate of treatment，fibrinogen （Fbg），platelet aggregation test （PAgT），prothrombin time （PT），hospitalization time，and symptom relief time were compared between the two groups.Results The total incidence rate of adverse cardiovascular events was 5.00%in the observation group，which was significantly lower than that in the control group accounting for 25.00%，and the difference was statistically significant （P＜0.05）.The total effective rate of treatment in the observation group was 87.50%，which was significantly higher than that in the control group accounting for 67.50%，and the difference was statistically significant（P＜0.05）.There were no significant differences in Fbg，PAgT and PT between the two groups before treatment（P＞0.05）.The Fbg and PagT after treatment in the two groups were lower than those before treatment，the PT was shorter than that before treatment，and the differences were statistically significant（P＜0.05）.The Fbg and PagT after treatment in the observation group were lower than those in the control group，the PT was shorter than that in the control group，and the differences were statistically significant （P＜0.05）.The hospitalization time and symptom relief time in the observation group were shorter than those in the control group，and the differences were statistically significant（P＜0.05）.Conclusion The application of Rosuvastatin combined with Ticagrelor can obtain a remarkable effect in the treatment of patients with coronary heart disease undergoing percutaneous coronary intervention and it is worthy of clinical application and promotion.
黄毅；陈文广；崔跃；李昌利；莫介超. 行经皮冠状动脉介入治疗的冠心病患者实施瑞舒伐他汀联合替格瑞洛治疗的效果[J]. 中国当代医药, 2019, 26(4): 63-65转69.
HUANG YiCHEN Wen-guang CUI Yue LI Chang-liMO Jie-chao. Effect of Rosuvastatin combined with Ticagrelor in the treatment of patients with coronary heart disease undergoing percutaneous coronary intervention. 中国当代医药, 2019, 26(4): 63-65转69.
京公网安备 11010502046607号